Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen

Stakeholder matrix (PDF 261 KB)

Review proposal paper (PDF 292 KB)

TA259 Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): press release information

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): final appraisal determination information

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): final appraisal determination guidance (PDF 337 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): response to comments on the appraisal consultation information

Response to consultee, commentator and public comments on the Appraisal consultation document (PDF 220 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): comments on the appraisal consultation information

Janssen (PDF 378 KB)

The Prostate Cancer Charity (PDF 172 KB)

Prostate Cancer Support Federation (PDF 83 KB)

British Association of Urological Surgeons (PDF 47 KB)

British Uro-Oncology Group (PDF 34 KB)

Cancer Research UK (PDF 67 KB)

Royal College of Physicians (PDF 75 KB)

Department of Health (PDF 21 KB)

NHS Hertfordshire (PDF 180 KB)

NHS Bradford and Airedale (PDF 139 KB)

Commissioning Support Appraisals Service (PDF 116 KB)

National Collaborating Centre for Cancer (PDF 118 KB)

Institute of Cancer Research (PDF 2.17 MB)

Evidence Review Group critique of extra information from Janssen (PDF 209 KB)

Comments on the Appraisal consultation document received from the public through the NICE website (PDF 1.43 MB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): update on scheduling (PDF 58 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): appraisal consultation

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): appraisal consultation information

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): evaluation report

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): pre-meeting briefing (PDF 242 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): Evidence Review Group report (PDF 744 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): Evidence Review Group report - factual accuracy check (PDF 105 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): manufacturer's submission (PDF 1.42 MB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): clarification

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): NICE clarification letter (PDF 156 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): manufacturer response to the NICE clarification letter (PDF 480 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): patient group, professional group and NHS organisation submission statements

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): Prostate Cancer Charity (PDF 91 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): Prostate Cancer Support Federation (PDF 96 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): Prostate Cancer Support Network (PDF 29 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): British Uro-Oncology Group (PDF 30 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): Royal College of Physicians on behalf of the NCRI/RCP/RCR/ACP/JCCO (PDF 38 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): NHS Bradford and Airedale (PDF 262 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): NHS Hertfordshire (PDF 43 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): expert written personal statements

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): Gunn (PDF 66 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): Shah (PDF 50 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): Staffurth (PDF 60 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): Syndikus (PDF 7.9 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): Watson (PDF 40 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): EIA form (guidance development) (PDF 76 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): EIA form (PDF 12 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): final scope (PDF 57 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): final matrix (PDF 56 KB)

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): comments on the draft scope (PDF 251 KB)

Prostate cancer (meta castration resistant) - abiraterone: appendix B - draft scope for consultation (pre-referral) January 2011 (PDF 57 KB)

Prostate cancer (meta castration resistant) - abiraterone: appendix C - provisional matrix (pre-referral) January 2011 (PDF 40 KB)